Novartis AG stock (CH0012005267): oncology focus and AI deals keep investors watching

Novartis AG continues to refine its focus on oncology, immunology and cardiovascular diseases while expanding in digital and AI-enabled drug discovery, developments that keep its New York–listed shares in the sights of many US and European investors, according to recent company disclosures and market data from early June 2026, including price information compiled by MarketBeat as of 06/05/2026.

As of: 08.06.2026

By the editorial team – specialized in equity coverage.

Novartis AG: core business model

Novartis describes itself as a focused innovative medicines company built around specialty pharmaceuticals in high-value therapeutic areas such as oncology, immunology, neuroscience and cardiovascular disease, following a series of portfolio simplifications and spin-offs that removed its generics and eye-care businesses in earlier years, according to company profile information on its corporate site as of 05/2026.Novartis company profile as of 05/2026

The group operates predominantly through its innovative medicines segment, concentrating on patented drugs that often target serious or chronic conditions where demand tends to be less sensitive to short-term economic cycles, a positioning that many investors view as defensive when compared with more cyclical industries, according to business descriptions published by the company in its investor materials as of 03/2026.Novartis investor overview as of 03/2026

Research and development remains central to the business model, with Novartis emphasizing a multi-platform strategy that spans small molecules, biologics and advanced therapies such as cell and gene treatments, and it highlights the role of data science and digital technologies in improving the probability of success and speed of its clinical pipeline, according to its R&D strategy presentations and public statements as of 04/2026.Novartis R&D strategy as of 04/2026

Main revenue and product drivers for Novartis AG

Novartis’ revenue base is concentrated in a set of so?called “in-market” and “growth” brands, many in oncology and immunology, which the company repeatedly cites as key sales engines in its financial reports, including its most recent annual report for the 2024 financial year published in 02/2025.Novartis annual report 2024 as of 02/2025

In oncology, Novartis generates significant revenue from targeted cancer therapies and hematology products, and has flagged several newer oncology launches as important growth pillars for the medium term, with their performance closely watched by market participants, according to product portfolio summaries in its 2024 annual reporting released in February 2025.Novartis annual report 2024 as of 02/2025

Beyond oncology, immunology and neuroscience medicines contribute meaningfully to group sales, and the company has called out cardiovascular drugs as another strategic category, pointing to opportunities in heart failure and related conditions in investor presentations from 2025 and early 2026 that outline its medium-term portfolio priorities.Novartis investor presentations as of 03/2026

The group is also investing in advanced therapies, including gene therapies for rare diseases and cell-based oncology treatments, which currently represent a smaller share of revenue but are positioned as potential long-term drivers, according to its pipeline disclosures and scientific updates released through 2025 and early 2026 on its science and R&D pages.Novartis pipeline overview as of 04/2026

Conclusion

Novartis AG today presents itself as a focused, innovation-driven pharmaceutical group with a strong orientation toward oncology, immunology and cardiovascular diseases and a growing interest in data- and AI-supported drug development, based on its corporate communications and investor materials through early 2026.Novartis investor information as of 03/2026 For US investors, the New York listing of NVS shares offers exposure to a large-cap European healthcare company whose revenues are significantly influenced by the US pharmaceuticals market, a factor that many portfolios consider when diversifying internationally yet remaining tied to US healthcare demand.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.